Company intelligence / Profile preview
SK bioscience
Seongnam-si, South Koreaskbioscience.com ↗
- Ownership
- Public · 302440
- Employees
- ~1101
- Development stage
- Commercial
01
Overview
Successfully developed South Korea's first COVID-19 vaccine (SKYCovione™). Phase III trials completed for next-gen pneumococcal vaccine with Sanofi. WHO-prequalified vaccines including SKYCellflu® and SKYVaricella®.
- Therapeutic areas
- Psychiatry
- Modalities
- Recombinant proteins
- Industry
- Biotech
02
Drug pipeline
23 assets22 more assets in the full pipeline.
03
Financials
- Market cap
- $2.2B
- Total revenue
- $481.2M
- Enterprise value
- $2B
Beyond the preview
Go deeper on SK bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SK bioscience.